Neil Clelland joins Fixed Phage as a Commercial Director

DATE: 3rd June 2022

Fixed Phage, (the “Company”) the UK biotechnology company harnessing the sustainable, specific power of bacteriophage (phage) to solve global bacterial challenges in animal and human health and personal care, today announces the appointment of Dr Neil Clelland as Commercial Director.

Dr Clelland’s appointment comes as the Company has leveraged significant investor funding from Scottish Enterprise and private investors, to upgrade its bespoke phage facilities at the West of Scotland Science Park along with the recruitment of specialist scientists to complement its expert team, to accelerate key product validation milestones and accelerate the adoption of the Fixed Phage unique anti-microbial platform.

David Browning, CEO of Fixed Phage said: “We are delighted to welcome Neil to the Fixed Phage team. Our unique phage-based antimicrobial platform, protected by robust intellectual property, is now close to market with the promise of delivering sustainable, global solutions to bacterial problems, including antibiotic resistance, across a range of industries including, food freshness, animal and human health and personal care.

Neil’s tremendous knowledge and applied experience in negotiating global licence deals and product launches within these key sectors will be important in accelerating market adoption and impact”.

Neil Clelland added: “I am excited to be joining Fixed Phage at such an important time and to establish sustainable commercial development alongside the highly experienced leadership team. With a broad range of applications, the company’s core phage stabilisation technology provides solutions to tackle bacterial challenges in animal health, food production, human health, and personal care. Realising market adoption and impact opportunities across these industries and globally highlights this diverse and sustainable biocontrol as an alternative solution.”

Related Articles